logo

For the Inventor, By the Inventor

Lausanne, Switzerland

Danila Valmori

USPTO Granted Patents = 15

Average Co-Inventor Count = 2.5

ph-index = 4

Forward Citations = 58(Granted Patents)


Location History:

  • Lausanne, CH (2000 - 2010)
  • New York, NY (US) (2008 - 2011)
  • Saint Herblain, FR (2011 - 2015)

Company Filing History:

goldMedal15 out of 525 
 
Ludwig Institute for Cancer Research Limited
 patents

Years Active: 2000-2015

Loading Chart...
15 patents (USPTO):Explore Patents
1. 9200047 - SSX-2 peptides presented by HLA class II molecules (2015-12-01),
2. 8008464 - SSX-4 peptides presented by HLA class II molecules (2011-08-30),
3. 7989587 - SSX-2 peptides presented by HLA class II molecules (2011-08-02),
4. 7910696 - Ssx-2 peptides presented by hla class II molecules (2011-03-22),
5. 7858743 - SSX-4 peptides presented by HLA class II molecules (2010-12-28),
6. 7713714 - Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof (2010-05-11),
7. 7429639 - SSX-2 peptides presented by HLA class II molecules (2008-09-30),
8. 7344879 - Isolated nucleic acid molecules which encode peptides that bind to HLA molecules, and uses thereof (2008-03-18),
9. 6605711 - NY-ESO-1 peptide derivatives, and uses thereof (2003-08-12),
10. 6417165 - NY-ESO-1-peptide derivatives, and uses thereof (2002-07-09),
11. 6384190 - Isolated decapeptides which bind to HLA molecules (2002-05-07),
12. 6368857 - Method for provoking proliferation of cytolytic T cells via the use of decapeptides which complex with HLA-A2 molecules (2002-04-09),
13. 6326200 - Isolated nona-and decapeptides which bind to HLA molecules, and the use thereof (2001-12-04),
14. 6277956 - Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof (2001-08-21),
15. 6025470 - Isolated nona- and decapeptides which bind to HLA molecules, and the use (2000-02-15),

Title: Danila Valmori: Innovator in Cancer Research

Introduction

Danila Valmori is a prominent inventor based in Lausanne, Switzerland. She has made significant contributions to the field of cancer research, particularly in the development of innovative peptides that target tumor-associated genes. With a total of 15 patents to her name, Valmori is recognized for her groundbreaking work in immunology.

Latest Patents

Valmori's latest patents include the development of SSX-2 peptides presented by HLA class II molecules. This invention describes HLA class II binding peptides encoded by the SSX-2 tumor-associated gene. The peptides stimulate the activity and proliferation of CD4T lymphocytes, providing methods and products for diagnosing and treating conditions characterized by the expression of the SSX-2 gene. Another significant patent involves SSX-4 peptides presented by HLA class II molecules, which similarly describe HLA class II binding peptides encoded by the SSX-4 tumor-associated gene. These peptides also stimulate CD4T lymphocyte activity and proliferation, offering diagnostic and therapeutic avenues for conditions related to the SSX-4 gene.

Career Highlights

Danila Valmori is affiliated with the Ludwig Institute for Cancer Research Limited, where she continues her research and development efforts. Her work has been instrumental in advancing the understanding of tumor immunology and the potential for targeted therapies.

Collaborations

Valmori collaborates with notable colleagues in her field, including Pedro Romero and Jean-Charles Cerottini. These partnerships enhance her research capabilities and contribute to the advancement of cancer treatment methodologies.

Conclusion

Danila Valmori's innovative work in cancer research, particularly through her patented peptides, showcases her commitment to improving diagnostic and therapeutic strategies. Her contributions are vital in the ongoing fight against cancer, and her collaborations further strengthen the impact of her research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…